Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris.~* Must have a minimum of ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and ≤ 2 nodulocystic lesions at baseline on the face.~* Must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment.~Exclusion Criteria:~* Female subjects who are pregnant, nursing or planning to become pregnant during study participation.~* Have a history of hypersensitivity or allergy to tazarotene, retinoids and/or any of the study medication ingredients.~* Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Test (Type: EXPERIMENTAL): Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
- Reference (Type: ACTIVE_COMPARATOR): TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)

Based on this trial design, predict the completion outcome and termination type (if applicable).